Is ABUS or KURA more profitable?

ABUS runs the higher net margin — ABUS at 84.23% versus KURA at -384.30%.

How have ABUS and KURA total returns compared?

Over the past 10 years, ABUS delivered 2.93% and KURA delivered 5.98% annualized total return. Past performance doesn't predict future results.

Arbutus Biopharma Corp (ABUS) vs Kura Oncology, Inc. (KURA)

A side-by-side comparison of Arbutus Biopharma Corp and Kura Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABUS

Arbutus Biopharma Corp

$888M

$4.50HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

KURA

Kura Oncology, Inc.

$926M

$10.43HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

Total return — ABUS vs KURA

growth of $100 · dividends reinvested · last 10y

ABUS +38.6% (+3.3%/yr)KURA +85.0% (+6.3%/yr)KURA compounded faster over this window

ABUS KURA

ABUS vs KURA: by the numbers

•KURA is the larger company ($926M vs $888M market cap).
•ABUS is profitable (84.23% net margin) while KURA runs a net loss (-384.30%).

Metrics side by side

Valuation

Metric	ABUS	KURA
P/E ratio	5.76	N/A
Forward P/E	6.07	N/A
P/S ratio	4.89	11.99
P/B ratio	3.43	19.12
EV / EBITDA	5.92	N/A

Profitability

Metric	ABUS	KURA
Gross margin	99.98%	94.73%
Operating margin	-192.08%	-449.94%
Net margin	84.23%	-384.30%
ROE	59.16%	-612.78%
ROIC	54.39%	-67.13%

Growth (annualized)

Metric	ABUS	KURA
Revenue CAGR (5Y)	85.17%	N/A
Total return CAGR (5Y)	2.19%	-10.73%

Frequently asked

Is ABUS or KURA more profitable?: ABUS runs the higher net margin — ABUS at 84.23% versus KURA at -384.30%.
How have ABUS and KURA total returns compared?: Over the past 10 years, ABUS delivered 2.93% and KURA delivered 5.98% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABUS analysis Full KURA analysis Interactive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratio Arbutus Biopharma ROE Kura Oncology ROE Arbutus Biopharma operating margin Kura Oncology operating margin Arbutus Biopharma revenue growth Kura Oncology revenue growth Arbutus Biopharma free cash flow Kura Oncology free cash flow

Arbutus Biopharma & Kura Oncology appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.